Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab in Metastatic Nasopharyngeal Carcinoma
NCT04872582Phase 2Unknown
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in nasopharyngeal carcinoma (NPC). Status: unknown.
02
Drugs
sintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04872582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872582.